naratuximab emtansine   Click here for help

GtoPdb Ligand ID: 9949

Synonyms: IMGN-529 | IMGN529 | K7153A-SMCC-DM1
Immunopharmacology Ligand
Compound class: Antibody
Comment: Naratuximab emtansine (IMGN529) is a CD37- targeting antibody drug conjugate carrying a potent anti-mitotic agent (maytansinoid DM1) payload. This ADC is being investigated for clinical efficacy as a treatment for B cell malignancies, with empahsis on diffuse large B cell lymphoma (DLBCL) in light of preliminary results from the phase 1 clinical trial NCT01534715 [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
The in vitro and in vivo (in NHL and CLL xenograft models) anti-tumour cell immune effector (intrinsic to the anti-CD37antibody) and anti-mitotic (due to the maytansinoid conjugate) activities of IMGN529 were reported by Deckert et al. in 2013 [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD37 molecule Primary target of this compound Hs Antibody Binding 9.3 pEC50 - 1
⤷ pEC50 9.3 (EC50 5x10-10 M) [1]
Description: Binding affinity to CD37 antigen–positive cells as measured by flow cytometry.